Medivation investors hoping for a windfall will be disappointed to hear that on December 20, 2012 a California judge ruled
The results of the phase 3 clinical trial of dasatinib (Sprycel) plus docetaxel/prednisone versus placebo and docetaxel/prednisone in men with castration-resistant metastatic prostate cancer (CRPC) are expected soon.
Radium-223 (Alpharadin) is a novel bone targeted treatment for advanced prostate cancer.
With the collapse of the Dendreon share price today following poor sales data (Adam Feuerstein on The Street has an excellent write up about this), attention has again focused on the prostate cancer market.
One of the sessions that I attended at the 2011 annual meeting of the American Urological Association (AUA) focused on research into advanced prostate cancer. A particularly thought provoking presentation was:
I am off to Washington DC tomorrow for the annual meeting of the American Urological Association (AUA).